Edition:
United Kingdom

Neos Therapeutics Inc (NEOS.OQ)

NEOS.OQ on NASDAQ Stock Exchange Global Market

8.70USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.70
Open
$8.75
Day's High
$8.80
Day's Low
$8.52
Volume
62,325
Avg. Vol
134,699
52-wk High
$13.15
52-wk Low
$5.53

Chart for

About

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to... (more)

Overall

Beta: --
Market Cap(Mil.): $255.53
Shares Outstanding(Mil.): 28.08
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Neos Therapeutics Reiterates Confidence In Strategic Plan And Value Creation Opportunities

* NEOS THERAPEUTICS REITERATES CONFIDENCE IN STRATEGIC PLAN AND VALUE CREATION OPPORTUNITIES

20 Feb 2018

BRIEF-Jack Schuler Reports 8.1 Pct Passive Stake In Neos Therapeutics

* JACK SCHULER REPORTS 8.1 PERCENT PASSIVE STAKE IN NEOS THERAPEUTICS INC AS ON DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2nOrQlw) Further company coverage:

08 Feb 2018

BRIEF-Neos Therapeutics reports Q3 loss of $0.58/shr

* Neos Therapeutics reports third quarter 2017 financial results

08 Nov 2017

BRIEF-PDL Biopharma urges Neos Therapeutics to provide update on sale process

* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process

08 Nov 2017

BRIEF-Neos Therapeutics receives paragraph IV certification from Teva Pharmaceuticals USA

* Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt​

01 Nov 2017

Neos Therapeutics to consider other offers after PDL snub: sources

U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc , will consider offers from other potential buyers, according to people familiar with the matter.

31 Oct 2017

CORRECTED-Neos Therapeutics to consider other offers after PDL snub -sources

Oct 31 U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter.

31 Oct 2017

BRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma

* Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​

26 Oct 2017

BRIEF-PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share

* PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash

26 Oct 2017

BRIEF-Neos therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

18 Oct 2017

Competitors

  Price Chg
Eli Lilly and Co (LLY.N) $78.75 +1.56
Pfizer Inc. (PFE.N) $36.26 +0.52
Concordia International Corp (CXR.TO) $0.90 0.00
Novartis AG (NOVN.S) CHF79.38 -0.60
Shire PLC (SHP.L) 3,024.00 -13.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates